Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $45.75 USD
Change Today +0.59 / 1.31%
Volume 766.2K
NUS On Other Exchanges
New York
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

nu skin enterprises inc - a (NUS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/7/15 - $62.87
52 Week Low
07/27/15 - $38.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NU SKIN ENTERPRISES INC - A (NUS)

nu skin enterprises inc - a (NUS) Details

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex brands worldwide. The company offers skin-care systems and treatment products, such as ageLOC Spa systems, ageLOC Tru Face Essence Ultra anti-aging skin care serum, and ageLOC Transformation anti-aging skin care system, as well as other cosmetic, personal care, and hair care products. It also provides LifePak; ageLOC R2 nutritional supplements; and ageLOC TR90 weight management and body shaping systems. In addition, the company is involved in the research and product development of aging, including the influence of certain ingredients on gene expression. It sells its products directly, as well as through its retail stores and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

24,350 Employees
Last Reported Date: 03/2/15
Founded in 1984

nu skin enterprises inc - a (NUS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $553.9K
President of Global Sales and Operation
Total Annual Compensation: $553.9K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $595.5K
Vice President, General Counsel and Secretary
Total Annual Compensation: $455.7K
Compensation as of Fiscal Year 2014.

nu skin enterprises inc - a (NUS) Key Developments

Nu Skin Enterprises Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter of 2015 and Full Year 2015

Nu Skin Enterprises Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $560,209,000 against $650,027,000 a year ago. Operating income was $71,801,000 against $54,737,000 a year ago. Income before provision for income taxes was $69,043,000 against $33,618,000 a year ago. Net income was $44,657,000 or $0.75 per diluted share against $19,507,000 or $0.32 per diluted share a year ago. Cash flow from operations for the quarter was $85.4 million. For the six months, the company reported revenue of $1,103,541,000 against $1,321,088,000 a year ago. Operating income was $140,447,000 against $155,934,000 a year ago. Income before provision for income taxes was $125,421,000 against $117,307,000 a year ago. Net income was $80,939,000 or $1.35 per diluted share against $74,361,000 or $1.22 per diluted share a year ago. The company provided earnings guidance for the third quarter of 2015 and full year 2015. The company projects second-half local-currency revenue growth of approximately 15%. The company’s prior guidance anticipated a negative foreign currency impact of 7% in the third and fourth quarters. The company now projects a negative impact of 10% to 11%. Given this impact, the company anticipates third-quarter revenue will be in the $600 million to $620 million range with earnings per share of $0.96 to $1.00. The company anticipates annual revenue to be in the $2.40 billion to $2.44 billion range, with earnings per share of $3.47 to $3.55 which includes a $0.12 expense associated with the Venezuela foreign currency charge in the first quarter of this year. Excluding this charge, earnings guidance would be in the range of $3.59 to $3.67. Including currency impact, this guidance reflects second-half reported revenue growth of between 5% and 6%.

Nu Skin Enterprises Inc. Declares Quarterly Dividend, Payable on Sept. 16, 2015

Nu Skin Enterprises Inc. announced that its board of directors has declared a quarterly dividend of $0.35 per share, which will be paid on Sept. 16, 2015, to stockholders of record on Aug. 28, 2015.

Nu Skin Enterprises Inc. to Report Q2, 2015 Results on Aug 06, 2015

Nu Skin Enterprises Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUS:US $45.75 USD +0.59

NUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GNC Holdings Inc $46.33 USD +0.35
Telecom Plus PLC 1,114 GBp +28.00
Tupperware Brands Corp $51.27 USD +0.61
USANA Health Sciences Inc $145.50 USD -3.42
Vitamin Shoppe Inc $35.57 USD +0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation NUS Industry Range
Price/Earnings 14.1x
Price/Sales 1.1x
Price/Book 2.9x
Price/Cash Flow 13.5x
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NU SKIN ENTERPRISES INC - A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at